Cardiome Pharma (CRME) Gains on FDA Filing

Cardiome Pharma Corp.

shares acquired 2.9% to $6.45, on word it has filed with the FDA's Office of Orphan Products Development a request for orphan drug designation for an oral formulation of vernakalant hydrochloride, under the FDA's Orphan Drug Act. Share volume was 1,400, compared to an all-day average of 37,000